10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
CytoMed Therapeutics does not have enough data to calculate 10-Year ROIIC %.
CytoMed Therapeutics 10-Year ROIIC % Historical Data
The historical data trend for CytoMed Therapeutics's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoMed Therapeutics's 10-Year ROIIC %
For the Biotechnology subindustry, CytoMed Therapeutics's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics's 10-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's 10-Year ROIIC % falls into.
CytoMed Therapeutics 10-Year ROIIC % Calculation
CytoMed Therapeutics's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -2.8858655 (Dec. 2023) - (Dec. 2013) )
/
( 2.141 (Dec. 2023) - (Dec. 2013) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
CytoMed Therapeutics 10-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of CytoMed Therapeutics's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoMed Therapeutics (CytoMed Therapeutics) Business Description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GDTC has been successfully added to your